ArticleCost effectiveness and resource allocation : C/E2025

Cost-utility analysis of olaparib assisted targeted therapy for BRCA mutation HER2-negative early breast cancer in China and in the United States.

Chenxia Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.